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Abstract
Coronavirus disease 2019 (COVID-19)
has dramatically changed our lives. In the
past months, hospitals were saturated of
patients; therefore, it is still important to
have simple and standardized prognostic
factors and to evaluate the efficacy and safe-
ty of medications commonly used for
COVID-19. We aimed to collect data of the
patients hospitalized in Internal Medicine
and Geriatrics Wards at the University
Hospital (Policlinico) ‘P. Giaccone’ in
Palermo, Italy (COMEPA, COVID-19
Medicina Policlinico Palermo), with the
main purpose of finding prognostic tools
that can be easily used in clinical practice in
order to identify patients hospitalized
for/with COVID-19 at higher risk of nega-
tive outcomes, such as mortality, transfer to
Intensive Care Unit (ICU) and institutional-
ization, as well as evaluating the
efficacy/safety of medications commonly
used for COVID-19. For reaching these
aims, the medical records of approximately
600 patients will be recorded, having data on
several parameters and including as out-
comes mortality, ICU placement, institution-
alization. With the COMEPA study, we
therefore plan to update current literature,
giving new data on prognostic factors and
on the efficacy/safety of some medications
used for COVID-19.
Introduction
In March 2020, the World Health
Organization declared the coronavirus dis-
ease 2019 (COVID-19) outbreak as global
pandemic.1 After more than one year of this
outbreak that has dramatically changed our
lives, more than 83 million people were
affected by COVID-19, with over three mil-
lion deaths in the world.2 All the National
Health Systems faced the relevant problem
of availability of hospital and Intensive
Care Unit (ICU) beds during the COVID-19
epidemic.3
For example, in the United States, sev-
eral hospitals were saturated during the first
two waves of COVID-19, particularly ICU
beds.4-6 In Italy, the COVID-19 outbreak
caused similar issues, putting the hospitals
and medical staff under psychological pres-
sure.7 In Italy, different waves during 2020
and 2021 were present followed by an
extensive amount of hospitalizations
decreasing the resilience of the Italian
healthcare system.8 The limited capacity of
hospitals were among the most challenging
issues facing authorities.8
The limited amount of hospital beds,
particularly in ICU, indicates the necessity
of a precise stratification of patients follow-
ing standardized prognostic factors.9 A liv-
ing systematic review found several prog-
nostic models prepared during COVID-19
outbreak, but all these models were rated at
high or unclear risk of bias.10 In this sense,
it would be helpful to have simple and inex-
pensive tools to identify the patient at high-
er risk of death and other relevant out-
comes, such as ICU transfer and institution-
alization.10
Given this background, we aimed to
collect data of the patients hospitalized in
Internal Medicine and Geriatrics Wards in
the University Hospital (Policlinico) ‘P.
Giaccone’ in Palermo, Italy (COMEPA,
COVID-19 Medicina Policlinico Palermo),
with the main purpose of finding prognostic
tools that can be easily used in clinical prac-
tice in order to identify patients hospitalized
for/with COVID-19 at higher risk of nega-
tive outcomes, such as mortality, transfer to
ICU and institutionalization. Moreover, we
will assess the efficacy/safety of some med-
ications used for the empirical treatment of
COVID-19 in real-life experience. 
Materials and Methods
Data source and inclusion/exclusion
criteria
All patients aging >18 years and hospi-
talized in Internal Medicine or Geriatrics
Wards from 01st September 2020 to 30th
April 2021 in the University Hospital
(Policlinico) ‘P. Giaccone’ in Palermo,
Sicily, Italy will be enrolled in this study.
No other inclusion criteria will be proposed,
to better represent real-life hospitalized
people. The study was approved by the
Local Ethical Committee during the session
of the 28th April 2021 (number 04/2021). 
Data collection
The data from medical records will be
recorded in a standardized Microsoft Excel
file by resident doctors, supervised by expe-
rienced researchers.
Statistical analyses
Data on normality for the continuous
variables will be assessed using the
Kolmogorov-Smirnov test: if normality will
be satisfied, data will be presented as means
and standard deviation (SD) for quantitative
measures or as median and interquartile
range (IQR) if not normally distributed. For
categorical variables, absolute numbers
(and percentages) will be reported.
Depending on the outcome of interest,
Cox’s regression or logistic binary analysis
will be used, including the assessment of
potential covariates and confounders that
should be associated with the outcome of
interest having, at least, a -value <0.10. To
test the robustness of our results, we plan to
run sensitivity analyses (i.e., median age,
gender and others pertinent), reporting the p
for interactions. The propensity score will
be applied in case of analyses regarding the
analyses of medications, if necessary.11
All the analyses will be performed
using the SPSS 21.0 for Windows (SPSS
Inc., Chicago, IL, USA). All statistical tests
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will be two-tailed, setting a p-value <0.05
for the statistical significance. 
Results
We plan to enroll all the patients admit-
ted during the period mentioned before, for
a total of approximately 600 hospitalized
patients. 
Table 1 shows the demographic and
clinical information that we will record at
the admission. Other than demographic
information, data on physiological anamne-
sis will be collected. Moreover, we plan to
register clinical information at the hospital
admission also in terms of COVID-19 vari-
ants, onset of clinical symptomatology and
signs/symptoms of COVID-19, and vital
signs (e.g., body temperature, blood pres-
sure, cardiac and respiratory frequency). We
decided to record the presence and the
severity of comorbidities using the cumula-
tive illness rating scale (CIRS).12 The CIRS
uses a 5-point ordinal scale (score 1-5) to
estimate the severity of pathology in 13 dif-
ferent systems. Finally, we plan to record
and analyze the data regarding bio-humoral
and microbiological exams as well as the
data regarding CT scans, as fully reported in
Table 1. 
Table 2 shows the information that we
will record regarding therapy used during
the hospitalization against COVID-19
infection. Therefore, the database will
include information regarding oxygen ther-
apy, corticosteroids, heparins, antibiotics
(given by general practitioners and during
the hospitalization), and remdesivir. 
Finally, Table 3 illustrates the outcomes
of our investigation that will be mortality
(including the cause of death, if available
from death certificates), clinical recovery,
ICU and sub-ICU admission, and in case of
older patients, institutionalization. 
Discussion and Conclusions
With the COMEPA study, we aim to
enroll all the patients hospitalized for and
with COVID-19 infection during the last
months in our wards of Internal Medicine
and Geriatrics in Palermo, Italy. Overall,
about 600 patients will be enrolled giving a
picture of the clinical and bio-humoral char-
acteristics of the patients present in our
wards during 2020 and 2021, affected by
this condition. 
During the first wave (i.e., in the first
six months of 2020), Sicily was relatively
free from COVID-19 infection, as shown by
national data.13 However, in the second part
of 2020 and particularly during the first part
of 2021, the problem of COVID-19
becomes very important in Sicily, particu-
larly in the Palermo area.14 Therefore, to
have clinical and epidemiological data spe-
cific for this area could be relevant, also in
case of a new wave of this condition. 
We would like to discuss some peculiar
aspects of the COMEPA study. First, we
will assess the clinical importance of the
variants in this specific geographical area in
which no data are available in terms of mor-
tality or other negative outcomes, compared
to the most frequent variant present in Italy.
The presence of some variants, in fact, in
Italy and in Sicily is exponentially increas-
ing in these months. For example, the
English variant (lineage B.1.1.7) seems to
increase as prevalence in Sicily,15 even if
the prognostic value is still not entirely
clear.16 Moreover, we plan to analyze not
only the impact of the presence of some
medical conditions, but also the severity
using the CIRS. In this sense, very limited
data are nowadays present, but they could
be important to better understand if some
conditions are associated with a greater risk
of mortality than others.
Furthermore, we will assess the impact
of unidimensional (e.g., bio-humoral
exams) and multidimensional scores for the
prognosis in hospitalized patients affected
by COVID-19. In this sense, several prog-
nostic models were prepared during
COVID-19 outbreak, but all these models
were of moderate to poor quality, indicating
the necessity of verifying these scores in
other contexts and to find other tools for
predicting prognosis.10
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Table 1. The COMEPA study: demographic and general clinical information.
Domain                                                          Component
Demographics                                                                 Age, gender, date of hospital admission
Physiological anamnesis                                               Work (if any), smoking status, alcohol abuse, drug
addition
Clinical information at the hospital admission        Nasopharyngeal swab positive (date), presence of
                                                                                            variants, onset of the clinical symptomatology, signs
                                                                                            and symptoms of COVID-19, vital signs
Comorbidity assessment                                              Cumulative illness rating scale
Arterial blood gas analysis                                            Ph, pO2, pCO2, lactates, pO2/FiO2
Bio-humoral exams                                                        Standard exams (e.g., complete blood count, renal
                                                                                            function), hsCRP, pro-calcitonin, total cholesterol
                                                                                            (and its components), serum 25OHD, proBNP, TSH
Microbiological exams                                                  Urine and blood cultures, Legionella, pneumococcus
                                                                                            antigen, rectal swab
CT exams                                                                          Brain, chest, abdomen
Table 2. The COMEPA study: information regarding therapy.
Domain                                                          Details
Oxygen therapy                                                               Type, duration and quantity of oxygen administered
                                                                                            during the hospitalization
Corticosteroids                                                               Type and duration
Heparins                                                                           Type and duration
Antibiotics                                                                        Before and during hospitalization
Remdesivir                                                                       Duration
Table 3. The COMEPA study: outcomes.
Domain                                                          Details
Mortality                                                                            Date and cause
Clinical recovery                                                             Date
ICU admission                                                                 Date and exitus
Sub intensive care unit admission                             Date and exitus
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A relevant part of our work will be given
to medications used during hospitalization.
The topic of medications that could improve
prognosis during COVID-19 infection is of
critical importance. During these months
several therapeutically approaches were
tried, often without significant results. For
example, with our experience we understand
that oxygen should be given with positive
pressure early to our patients in order to
improve prognosis.17 However, some
debates still remain in mild to moderate
forms that are, on the contrary, frequently
hospitalized.18 Similarly, we can deal with
other medications commonly used for the
treatment of COVID-19 including corticos-
teroids,19 heparins20 or antibiotics. Finally,
since a consistent part of our patients was
treated with remdesivir, we will assess the
impact of this antiviral medication on the
clinical course of COVID-19.21 For remde-
sivir, in fact, which is commonly used in our
hospitals, a definitive word cannot be said in
terms of efficacy and safety. At the same
time, we believe that data regarding medica-
tions in observational studies are important
since they represent real-life experience in
which frailer people that are usually hospi-
talized but excluded by the randomized con-
trolled trials, are represented. 
In conclusion, with the COMEPA study,
we would like to explore the importance of
some prognostic factors and the
efficacy/safety of some medications used
for the empirical treatment of COVID-19
based on our real-life experience. We
believe that our data could be important for
better understanding some still not known
aspects of this condition in hospitalized
patients. 
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